Q-omics provides the consensus-scored RPL37P12 profile across patient tissues and cancer cell-line models. RPL37P12 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL37P12 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, RPL37P12 RNA expression shows 17,581 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where RPL37P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL37P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL37P12 survival associations across molecular data types. RPL37P12 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL37P12 RNA expression–survival associations across cancer types. High RPL37P12 expression shows unfavorable associations in UVM, STAD, LGG, BLCA and CHOL, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL37P12 RNA expression.
This table summarizes RPL37P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL37P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL37P12 shows lower tumor expression in BRCA and THCA and higher tumor expression in HNSC, KIRP, UCEC and CHOL. The HNSC box plot shows higher RPL37P12 RNA expression in tumor versus normal tissue (log2 FC = +0.408, t-test p < 0.001).
This table shows molecular features associated with RPL37P12 in patient tissues and cancer cell lines. In patient samples, RPL37P12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
